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The Smad family of intracellular signaling intermediates transduce signals downstream from the transforming growth factor
beta (TGF-b) family of receptor serine threonine kinases. The original member of this family, Smad1, has been shown to
mediate signals from receptors for the bone morphogenetic proteins (BMPs), a large group of ligands in the TGF-b
superfamily that mediate important developmental events. We have targeted the Smad1 gene in mice and created mutants
null at this locus. Smad1 mutant mice die at approximately 9.5 days postcoitum due to defects in allantois formation. In
Smad1 mutant mice, the allantois fails to fuse to the chorion, resulting in a lack of placenta and failure to establish a
definitive embryonic circulation. Although vasculogenesis is initiated in the mutant allantois, the vessels formed are
disorganized, and VCAM-1 protein, a marker for distal allantois development, is not expressed. Smad1 null fibroblasts are
till able to respond to BMP2, however, suggesting that the defect observed in the developing extraembryonic tissue is
aused by a very specific loss of transcriptional activity regulated by Smad1. Our data further demonstrate that although
ighly similar structurally, Smad proteins are not functionally homologous.
Key Words: TGF-b; Smads; allantois; BMP; targeted mutagenesis; VCAM-1; placenta.c
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The TGF-b superfamily of intercellular signaling mol-
ecules is a large, conserved family that regulates important
developmental events from early patterning to postnatal
development (Hogan, 1996; Letterio and Roberts, 1997;
Whitman, 1998). All TGF-b superfamily members studied
o date signal through a highly conserved mechanism of
ransmembrane receptors and receptor-activated, translo-
atable transcription cofactors called Smads. Ligand binds
o the type-II transmembrane serine–threonine kinase re-
1 Present address: Department of Cell Biology, Georgetown Uni-
versity Medical School, 3900 Reservoir Road NW, Washington,
D.C. 20007.
2 To whom correspondence should be addressed. Fax: 202-687-
823. E-mail: rj124@georgetown.edu.
3 Present address: University of California, San Diego School of
edicine, Medical Teaching Facility Room 252, 9500 Gilman
rive, La Jolla, California 92093-0627.
0012-1606/01 $35.00eptor which subsequently recruits and phosphorylates the
ype-I receptor kinase. Following type-I receptor activation
y phosphorylation, receptor-activated Smads (R-Smads)
ct as direct substrates for the kinase activity of the type-I
eceptor. Phosphorylated R-Smads associate with the com-
on Smad, Smad4, and this complex then translocates to
he nucleus where it is involved in mediating transcrip-
ional responses on target genes (Massague and Chen, 2000;
ill, 1999). Interactions between the R-Smads and type-I
eceptors are specific. Smad2 and Smad3 interact only with
eceptors for TGF-b or activin, while Smad1 and Smad5
interact with receptors for the BMP family (Massague,
1998). Smad activation has been shown to be essential for
mediating growth inhibitory and certain transcriptional
responses for all members of the TGF-b superfamily tested
thus far, although accessory pathways likely play an impor-
tant role in modulating this activity (Mulder, 2000; Miya-
zono, 2000).The BMPs, the largest family within the TGF-b super-
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158 Lechleider et al.family, regulate several key processes in development. For
example, Bmp4 has been shown to be a potent inducer of
ventral mesoderm during gastrulation in Xenopus laevis. In
the mouse, Bmp4 is also essential for gastrulation (Winnier
et al., 1995). Embryos with targeted disruption of both
alleles of Bmp4 die between 6.5 and 9.5 days postcoitum
(dpc), with the majority failing to progress beyond the egg
cylinder stage. Interestingly, targeted mutagenesis of Bmp2,
which is greater than 90% indentical to Bmp4, caused a
defect in closure of the proamniotic canal and defects in
heart formation, although embryos appeared to undergo
gastrulation normally (Zhang and Bradley, 1996). Other
BMPs appear to mediate effects later in development. Bmp7
(Op-1) is essential for eye and kidney development, while
loss of Bmp5 does not lead to a discernible phenotype
during development, but causes skeletal defects in postna-
tal life (Dudley et al., 1995; Karsenty et al., 1996; Storm et
al., 1994). Similarly, mutations in both type-II and type-I
receptors for BMPs cause severe developmental defects.
Targeted deletion of Bmpr-II (Beppu et al., 2000) as well as
Bmpr-IA, one of the two known type-I receptors for BMPs,
leads to death at the egg cylinder stage with a failure to
undergo gastrulation, as does mutation of Actr-IA, which
has been shown to bind to and activate Smad1 (Goumans
and Mummery, 2000).
Three Smad proteins have been shown to signal from
receptors of the BMP family. Smad1 was the first mamma-
lian Smad gene to be described and is structurally highly
similar to Drosophila mad. Smad5 and Smad8 are two
highly similar vertebrate isoforms that have not been as
well studied at a biochemical level (Hill, 1999). Smad1 is
phosphorylated and activated by the BMP receptors
BMPR-IA and BMPR-IB, the related activin receptor ActR-I
(Macias-Silva et al., 1998), and also Alk1 (Chen and Mas-
sague, 1999), an orphan receptor for which ligand specificity
remains uncertain. In developmental systems, Smad1 and
Smad5 can induce ventral mesoderm, similar to ectopic
expression of BMP receptors, and can block the dorsalizing
effects of activin (Lagna and Hemmati-Brivanlou, 1999).
Dominant inhibitory forms of Smad1 can block the ventral-
izing effects of constitutively active BMP receptors, and
overexpression of wild-type Smad1 can overcome loss of
signaling induced by dominant inhibitory forms of BMP
receptors (Graff et al., 1996). Taken together, these studies
emonstrate that Smad1 can mediate the principle effects
f BMP receptors in inducing ventral mesoderm formation
n Xenopus.
Studies of the roles of Smad1, Smad5, and Smad8 in
urine development suggest a more complicated picture
han that which has emerged from Xenopus. Expression
atterns of Smad1 suggest a role throughout development
Dick et al., 1998), although expression at around the time
f gastrulation has not been examined. Targeted disruption
f Smad5 revealed a role for this gene in vascular develop-
ent and patterning, yet mutant embryos underwent nor-
al gastrulation (Yang et al., 1999; Chang et al., 1999).Since Smad1 and Smad5 share approximately 92% aminocid identity and appear to be functionally homologous in
itro, we sought to further examine the role of Smad1 in
ammalian physiology by targeted disruption of Smad1 in
mbryonic stem (ES) cells and generation of mutant mice.
ur results indicate that, like Smad5 mutant mice, Smad1
ull mice proceed through gastrulation normally, but die in
idgestation due to defects in allantois development and
horioallantoic placenta formation. Together, these data
ndicate both redundant and specific roles for these two
ighly related proteins that signal from BMP receptors.
MATERIALS AND METHODS
Construction of the Smad1 targeting vector and generation of
Smad1 null mice. A mouse 129SvEv genomic library was
screened with a Smad1 probe and a 16-kb NotI fragment containing
exon 3 (Huang et al., 2000) was isolated. A targeting vector
containing approximately 8.5 kb on the 39 arm and 4.4 kb in the 59
arm was constructed in pPNT. The vector was electroporated into
TC1 129Sv/Ev ES cells (Deng et al., 1996), which were selected in
G418 and FIAU. Two correctly targeted clones as identified by
Southern blot analysis were injected into C57/B16 blastocysts and
chimeric mice generated for both clones. Chimeric males were
mated into 129Sv/Ev or NIH Black Swiss females and the F1 and
ubsequent generations intercrossed. There were no differences
bserved between the two clones used for this analysis.
Genotype analysis. Southern blot analysis was performed as
escribed on genomic DNA isolated from E9.5 embryos by using
he Trizol reagent (Gibco/Life Technologies) or from tail clips. PCR
enotyping of yolk sac DNA was performed by using the primers
9-gaagcacagcgagtacaatcct-39 and 59-cactgtgtggttttcgctcttt-39 for the
ild-type allele and 59-gaagcacagcgagtacaatcct-39 and 59-ccgct-
cctcgtgctttac-39 for the mutant, yielding products of 1.1 kb and 700
p, respectively. PCR conditions were: 94°C for 4 min then 35
ycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s with a final
xtension of 72°C for 7 min.
Western blot and reverse transcriptase–polymerase chain reac-
ion (RT-PCR) analysis. Protein extracts from 9.5-dpc embryos
ere separated by SDS-PAGE, transferred to PVDF membrane, and
robed with a mouse monoclonal antibody to Smad1 raised against
he full-length GST-fusion protein (Santa Cruz Biotechnologies).
enotypes were confirmed by Southern blotting of the genomic
NA isolated from the same embryos. The Smad1 antibody was
valuated for specificity by lack of cross-reactivity with other Smad
roteins, and blocking with GST–Smad1 fusion protein but not
ith GST alone (data not shown). The truncated Smad1 expression
onstruct was designed to express amino acids 1–212 of Smad1 in
he pCMV2-FLAG vector. Lysates of COS1 cells transiently trans-
ected with either the full-length or truncated Smad1 expression
onstruct are included as controls. RNA and DNA for genotyping
ere extracted from 9.5-dpc embryos by using Trizol (Life Tech-
ologies). cDNA was prepared by using a commercial kit (Life
echnologies) and PCRs were run by using standard conditions.
rimers were derived from the MH1 domain or spanning the linker
nd MH2 domain. b-Actin primers served as a control.
Histological analysis. Embryos were dissected free from the
uterus and the yolk sac reserved for genotyping. Embryos were
fixed in cold 4% paraformaldehyde and embedded in paraffin for
sectioning (5 mm) and staining by hematoxylin and eosin. Embryos
from wild-type crosses were stained with a rabbit polyclonal
anti-Smad1 antibody (Zymed) at 1:500 dilution in phosphate-
tained from a 129 Sv/Ev ES cell genomic library using a 59
T
G
159Smad1 Knockout Mousebuffered saline, washed, and detected with horseradish peroxidase
coupled secondary and diaminobenzamidine (Vector Labs) and
FIG. 1. Targeting of the Smad1 gene in the mouse. (A) Partial map
of the Smad1 genomic locus is shown (Top) with exon 3 which
contains the ATG translational start and continues to amino acid 215
near the end of the middle linker domain indicated. The targeting
vector was constructed by cloning the 59 ApaI–SmaI and 39 SmaI–
HindIII fragments into pPNT with the neomycin transcript oriented
in the reverse direction to the Smad1 gene. SpI, SpeI; HIII, HindIII; AI,
ApaI; BI, BamHI; XbI, XbaI. (B) Southern blotting of genomic DNA
extracted from 9.5-dpc embryos and digested with HindIII shows the
wild-type 6.5-kb and mutant 8.3-kb fragments. The probe was a
SmaI–HindIII fragment isolated from the genomic clone. Lanes 1 and
2, wild type; lanes 3, 4, and 6, heterozygous; lane 5, mutant. (C)
RT-PCR analysis of RNA from wild-type (lanes 1–3) or Smad12/2
(lanes 4–6) embryos. Primers are derived from the MH1 domain (lanes
1 and 4) or spanning the linker and MH2 domains (lanes 2 and 5).
Lanes 3 and 6 are b-actin controls. (D) Western blot analysis of
protein extracts from wild-type (lane 3) heterozygous (lane 4) and
mutant (lane 5) embryos as determined by Southern blotting. Lysates
from COS-1 cells transiently transfected with expression constructs
for full-length (lane 1) and truncated (lane 2) Smad1 are included as
controls. Smad1 is indicated by arrows. Note that there is no full-
length or truncated protein in lane 5, the mutant extract. There is a
prominent nonspecific band in all lanes just below the Smad1 band, as
well as other nonspecific bands.counterstained with hematoxylin. Flk-1 expression was analyzedby immunohistochemistry using a commercially available anti-
body (Chemicon). Whole-mount immunostaining for VCAM-1 was
performed basically as described (Kwee et al., 1995). Briefly, E8.5
embryos were fixed for 5 min in Dent’s fixative (80% methanol/
20% DMSO), rehydrated, blocked in BSA for 2 h, and incubated
overnight at 4°C with anti-VCAM-1 monoclonal antibody (Phar-
mingen). Following extensive washing in neutral buffered saline
with Tween 20, embryos were incubated overnight with secondary
antibody, washed, and incubated with colorimetric substrate.
Whole-mount in situ hybridization. Embryos at 8.5 dpc were
prepared and hybridized as described (Lowe and Kuehn, 2000). A
500-bp probe to the coding region of the mouse Vcam1 gene was
used. Antisense controls showed no hybridization (data not
shown). Embryos were photographed with a Leica MZ-12 stereomi-
croscope fitted with a standard 35-mm camera.
Cell culture and growth inhibition assays. Embryos at 9.5 dpc
were dissected free of maternal structures and minced in DMEM
containing 10% fetal bovine serum and antibiotics. Cells were
allowed to expand and surviving colonies were genotyped by both
PCR and Southern blot analysis, confirming genotypes as either
wild-type or homozygous null. For growth inhibition assays, 4 3
104 cells per well were plated in 24-well plates, treated as indicated
with BMP2 or TGF-b overnight, and [3H]thymidine incorporation
determined as described previously. Each experiment was repeated
at least once with similar results. Results are presented as the
mean 6 the SEM of triplicate wells from a single experiment.
RESULTS
Creation of a Smad1 targeting vector and generation of
ES cell heterozygotes. A Smad1 genomic clone was ob-
TABLE 1
Genotypes of Viable Offspring of Smad11/2 Intercrosses
Background
Genotypea
1/1 1/2 2/2
129Sv/Ev 24 (60) 16 (40) 0
129/Black Swiss 47 (39) 75 (61) 0
Note. Numbers in parenthesis are percent of total viable off-
spring.
a As determined at weaning.ABLE 2
enotypes at Various Stages of Development
Stagea
Genotypeb
1/1 1/2 2/2 Resorbed
8.5 8 (31) 12 (46) 6 (23) 0 (0)
9.5 16 (26) 36 (60) 6 (10) 2 (3)
10.5 11 (39) 13 (46) 2 (7) 2 (7)
11.5 5 (24) 12 (57) 0 (0) 4 (19)
a Days post coitum (dpc).
b As determined by PCR of embryo or yolk sac.
blanot
160 Lechleider et al.fragment of murine Smad1 cDNA as a probe. The targeting
vector was constructed to interrupt the third exon of Smad1
at the SmaI site by insertion of the neomycin resistance
gene driven by the PGK promoter in the reverse orientation
(Fig. 1). We call this allele Smad1tm1. Approximately 8.5 kb
of 59 flanking DNA and 4.4 kb of 39 flanking DNA were
cloned into the targeting vector pPNT. Following electro-
poration and selection in G418, 180 ES cell clones were
FIG. 2. Gross phenotype of the Smad1 null embryos. (A) 1/2 and (B
is indicated (arrowhead). (C) Embryos at 9.5 days, genotypes as indi
the bulbous, vascular allantois on the mutant embryo (arrow). The h
mutant (E) 9.5-dpc embryos with intact yolk sacs, genotypes as indica
cleared in glycerol. The mutant allantois (white arrows) in (E) is indic
which are clearly present in the normal embryo (arrows in D). al, alanalyzed by Southern blotting of HindIII digests of genomic dDNA. Proper targeting would yield an 8.3-kb fragment for
the mutant allele and a 6.5 fragment for the wild-type (Fig.
1). Twelve clones with likely targeting events were identi-
fied. Two of these clones were confirmed to have correct
targeting events by repeat Southern blotting following di-
gestion with ApaI and use of a 39 flanking probe (not
shown). Both Smad11/2 clones were injected into C57/B6
lastocysts to generate chimeric mice. Subsequent analyses
embryos at 8.5 dpc. Each embryo had seven somites. The allantois
. The mutant embryo is smaller and developmentally delayed. Note
ozygous embryo has normal umbilical vasculature. Normal (D) and
mbryos were dissected away from maternal tissues and the yolk sacs
. Note the failure of the mutant embryo (E) to form umbilical vessels,
is. Bar, 1 mm.) 2/2
cated
eter
ted. E
atedid not reveal any differences between the two clones.
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161Smad1 Knockout MouseThe targeting construct used could theoretically produce
a truncated form of Smad1 lacking the MH2 domain which
could potentially act as a dominant interfering or activating
mutant. RT-PCR analysis showed that no transcript span-
ning the insertion site was present in RNA extracted from
mutant embryos, but that a truncated message that could
potentially be translated into a C-terminally truncated
protein was still produced (Fig. 1C). In order to determine
whether any truncated or alternatively spliced protein prod-
uct was produced, we performed immunoblots on protein
FIG. 3. Expression of Smad1 at 8.5 days. (A) Low- and (B) high-
with a Smad1 antibody. Black arrows show positive Smad1 stainin
ys, yolk sac; n, neural fold. Scale bar, 25 mm (A), 100 mm (B).
FIG. 4. Allantoic and placental phenotype of Smad12/2 mutants
different embryos. The arrows in (A) indicate the collection of ce
(C–F). Wild-type (C, D) and mutant (E, F) placentas. The brackets
represented in (D) and (F). Horizontal arrows identify maternal bloo
bar, 100 mm (A, B, D, F), 500 mm (C, E).extracts purified from wild-type, heterozygous, and nullmbryos. Using a Smad1 monoclonal antibody, we con-
rmed that, although both the wild-type and heterozygous
mbryos expressed Smad1, no full-length Smad1 could be
etected in extracts from the Smad12/2 embryos. To con-
firm that the antibody could recognize a C-terminal trun-
cated Smad1 product, we created a Smad1 expression vector
(Smad1 1–212) which contains only the N-terminal amino
acids and represents the potential truncated protein pro-
duced. The Smad1 antibody recognized this truncated con-
struct, while no truncated product was detected in extracts
r view of transverse sections of wild-type 8.5-dpc embryos stained
ls, white are negative. v, vessel; b, blood; al, allantois; a, amnion;
B) Microscopic view of Smad12/2 allantois at 9.5 dpc from two
the amnion. Arrowheads demonstrate likely vascular structures
ate the chorionic plate, and the boxes in (C) and (E) are the areas
sels, vertical arrows identify embryonic vessels, absent in (F). Scalepowe
g cel
. (A,
lls at
indic
d vesfrom the heterozygous or null embryos. This confirms that
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162 Lechleider et al.the failure to identify Smad1 in the mutant extracts was
due to lack of protein and not inability of the antibody to
recognize the truncated product. The lack of full-length
transcript as demonstrated by RT-PCR and the failure to
detect a truncated protein by immunoblotting demonstrate
that we have correctly targeted the Smad1 gene in the
mouse, and that genetic targeting leads to a complete loss of
Smad1 protein production.
Loss of Smad1 leads to embryonic lethality in early to
midgestation due to a failure of chorioallantoic fusion.
Smad1 heterozygous animals were generated by crossing
the germ line chimeras into both 129Sv/Ev and Black Swiss
backgrounds. Heterozygotes from these matings were inter-
crossed and the relative proportion of Smad1 genotypes was
determined by PCR. From these matings, no Smad12/2
animals were recovered at weaning (Table 1). Analysis of
the intercrosses in the 129 background revealed dispropor-
tionately few heterozygous animals, although the cause for
this has not been determined. Smad1 heterozyogous adults
ere healthy and fertile, and no abnormalities were ob-
erved in mice kept for up to 6 months.
Analysis of timed pregnancies from Smad11/2 crosses
revealed Mendelian ratios of all three genotypes through 8.5
dpc (Table 2). Beginning at 9.5 dpc, resorptions and loss of
Smad12/2 embryos were evident. By 10.5 dpc, no viable
Smad12/2 embryos were identified, although occasional
small, poorly developed embryos were recovered. Gross
morphological analysis of Smad12/2 embryos at 8.5 dpc
revealed no obvious defects (Fig. 2B). Smad12/2 embryos had
comparable numbers of somites as wild types at 8.5 dpc,
and embryos recovered at this stage were generally of
similar size to wild-type or heterozygous embryos.
Smad12/2 embryos appeared to have a somewhat shortened
llantois compared to wild-type or heterozygous embryos,
lthough precise measurements of allantois length were not
ade. Although mutant embryos recovered at this stage
ad failed to develop a fully fused chorioallantoic placenta,
he same was true for a subset of wild-type and heterozy-
ous embryos and was not a striking defect. At 9.5 dpc,
owever, Smad12/2 embryos, although still viable as indi-
ated by a beating heart, showed obvious defects in umbili-
al vessel formation. In nearly all Smad12/2 embryos recov-
ered at 9.5 dpc, the allantois had failed to fuse to the
chorion, resulting in a lack of a chorioallantoic placenta and
failure to establish definitive embryonic circulation (Fig.
2E). The rare embryo in which chorioallantoic fusion took
place showed a poor connection between the chorion and
allantois, with a disorganized vascular plexus abutting the
chorion. No other gross morphological defects were ob-
served in the Smad12/2 embryos. In particular, unlike the
Smad5 mutants, no defects in turning, craniofacial, or
cardiac development were observed. Some Smad1 embryos
did display defects in yolk sac angiogenesis (data not
shown), but these did not appear to be as severe as the
defects observed with the loss of Smad5, and no abnormali-
ties in embryonic angiogenesis were noted.Smad1 protein expression and chorioallantoic placenta
efects. Immunohistological analysis of Smad1 at 8.5 dpc
howed widespread expression, with particularly high ex-
ression in the yolk sac (Fig. 3), and expression in nearly all
ells in the allantois. Microscopic analysis of the mutant
llantois at 9.5 dpc revealed a disorganized collection of
ells with some nests or channels of what appeared to be
ematopoietic cells (Figs. 4A and 4B). The mutant allantois
enetrated the amnion, although there was often a small
ollection of cells around the area of penetration through
he amnion (Fig. 4A). In some embryos, the fusion of the
llantois and amnion was more complete (Fig. 4B), with a
arge collection of cells at the junction of the allantois and
mnion. Despite this apparent disorganized proliferation,
he mutant allantois still appeared to organize into struc-
ures consistent with blood vessels (Fig. 4B).
Failure of chorioallantoic fusion lead to defects in the
lacenta. The placenta is a combined maternal–fetal organ
hat requires coordinated invagination by embryonic com-
onents into maternal tissue. In particular, vessel ingrowth
rom the embryonic allantois is required for proper
aternal–fetal oxygen and nutrient exchange. The first
vent in placental development is the fusion of the chorion
nd allantois that occurs around 8.5 dpc. As noted,
mad12/2 embryos failed to form proper chorioallantoic
usion. Examination of placentas revealed further defects in
lacental development (Figs. 4C–4F). By 9.5 dpc, normal
lacenta had developed a significant labyrinthine layer,
ith extensive vessel growth from the site of fusion into
he maternal component. In contrast, although maternal
essels can be seen in the labyrinthine layer of the mutant
lacenta as evidenced by maternal, unnucleated erythro-
ytes, no vessels derived from the embryo are evident, and
he chorionic plate is much smaller. The defect in vascu-
arization is not a primary defect in vasculogenesis, as
videnced by vessels visible in the mutant allantois (Figs.
B, 5A, and 5B), but is directly related to the failure of
llantoic fusion.
The allantois in Smad12/2 mutants forms vessels but
fails to express VCAM1. The allantois gives rise to the
umbilical vessels, and is one of the few sites in the embryo
that develops vessels through vasculogenesis (Downs et al.,
998). In order to determine whether the structures seen in
he mutant allantois represented vessels and hematopoietic
ells, we stained the mutant allantois for flk1. Flk1 is a
eceptor for VEGF, and is an early marker for hematopoietic
nd vascular endothelial cells. The Smad12/2 mutant
clearly expressed flk1 as determined by immunohistochem-
istry (Figs. 5A and 5B). Tubular structures lined by cells
resembling endothelial cells stained positively for flk1, as
did occasional cells within these structures. This demon-
strates that the mutant allantois is able to support vascu-
logenesis, despite the proliferative defect and failure to fuse
with the chorion.
To start to determine the molecular mechanism of the
failure of chorioallantoic fusion, we examined expression of
VCAM-1. The phenotype resulting from the loss of Smad1
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163Smad1 Knockout Mouseexpression closely resembles that of the loss of the inter-
cellular adhesion molecule VCAM-1. VCAM-1 in the adult
is expressed on endothelial cells and activated leukocytes.
In the embryo, VCAM-1 is expressed in the developing
allantois, heart, and yolk sac, beginning about 7.5 dpc. Loss
of VCAM-1 expression leads to embryonic lethality at
approximately E9.5 from lack of proper placental circula-
tion, similar to the phenotype seen with Smad1 (Kwee et
l., 1995; Gurtner et al., 1995). In order to determine
hether VCAM-1 expression was altered in the Smad1
knockout mice, we performed whole-mount immunostain-
ing of 8.5-dpc embryos with an antibody to VCAM-1. As
expected, VCAM-1 was expressed in the heart, allantois,
and yolk sac of both 1/1 (not shown) and 1/2 embryos
(Fig. 5C). In contrast, VCAM-1 expression was lost in the
Smad12/2 embryos, but loss of expression was restricted to
only the allantois (Fig. 5D). Expression levels in the heart
and yolk sac were comparable to that found in the wild-type
or heterozygous animals. Whole-mount in situ hybridiza-
tion, however, suggested that VCAM-1 message was still
expressed (Fig. 5E), but that this expression was variable.
Similarly, mTwist expression was also assayed by whole-
mount in situ hybridization, but no differences between
wild-type and mutant embryos were observed (data not
shown). These data suggest that, although we cannot detect
VCAM-1 protein in the mutant allantois, it may still be
present, as suggested by in situ hybridization results. Thus,
the role of VCAM-1 expression in the observed phenotype is
unclear.
Loss of Smad1 does not lead to loss of BMP2 responsive-
ness. Studies using Smad deficient cells have demonstrated
that Smad signaling is essential for growth-inhibitory and
some transcriptional responses activated by both TGF-b and
MP family ligands (Sirard et al., 2000; Yang et al., 1999). To
etermine whether Smad1 was necessary for BMP responses
n cultured cells, wild-type and Smad12/2 fibroblasts were
ultured from 9.5-dpc embryos and their responses to TGF-b
family ligands determined. Although TGF-b and BMPs can
timulate growth of mesenchymal cells under certain condi-
ions, under the growth conditions employed in these experi-
ents, both ligands were growth inhibitory. Treatment of
oth wild-type and Smad12/2 fibroblasts with 1 ng/ml of
TGF-b caused a significant growth inhibition (Fig. 6). Surpris-
ingly, treatment of both wild-type and Smad12/2 fibroblasts
with BMP2 also resulted in a significant growth inhibitory
response, with essentially equal IC50 values in both cell lines.
imilar results were obtained when transcriptional induction
f PAI-1 was examined, but the absolute induction in either
ild-type or mutant cells by BMP2 was lower than that
bserved with TGF-b (data not shown). This finding suggests
that Smad1 is not a critical mediator of the BMP2 growth
inhibitory response, and that other Smad proteins or auxiliary
pathways can mediate this response. They further suggest that
the defect seen in the Smad1 mutant embryos is a very
specific one which cannot be corrected by Smad5.DISCUSSION
The TGF-b superfamily is a large family of growth and
differentiation factors that play diverse roles during mam-
malian development. Despite the large number of ligands
and the diversity of responses they elicit, the signaling
pathway from the cell surface receptors to the nucleus is
alarmingly simple. To date, only five R-Smads have been
identified: Smad1, Smad2, Smad3, Smad5, and Smad8. It is
apparent, therefore, that individual Smad proteins will have
specific roles based on both the signals that lead to their
activation and their subsequent participation in specific
transcriptional complexes. Additional levels of control will
include temporal and spatial regulation of expression, as
well as positive and negative regulation by other signaling
pathways.
When overexpressed in biochemical assays, Smad1 and
Smad5 have been shown to be largely homologous. Both
proteins are phosphorylated by BMP family receptors, and
can mediate signals from these receptors to activate gene
transcription of artificially constructed reporter constructs.
Differences in the abilities of these two closely related
transcription factors to recognize or regulate target genes in
situ have not been demonstrated. It is clear from genetic
studies in the mouse, however, that Smad1 and Smad5
have distinct but partially overlapping functions during
mammalian development. The defect observed in Smad12/2
animals, failure of chorioallantoic fusion, is quite specific.
Although one group observed milder allantois defects in
Smad5 null mice, these were not seen in mice generated in
the laboratory of one of the authors of this report (C. Deng).
Unlike the defect described by Chang et al. (1999) for mice
utant at the Smad5 locus, Smad1 mutant mice rarely
demonstrated full extension of the allantois to the chorion.
This suggests that Smad1 plays a distinct role in regulating
allantois growth and fusion with the chorion, perhaps at an
earlier stage than Smad5. Similarly, Smad1 mutant em-
bryos did not demonstrate the range or severity of defects
seen in the Smad5 mutants reported by either group. For
example, although some defects in yolk sac angiogenesis
were observed in Smad1 mutants (compare the vitelline
vessels in Fig. 2E with 2D), these were mild compared to the
defects reported for Smad5 mutants. Similarly, no gross
morphological or histological defects were observed in
cardiac or foregut development in Smad12/2 embryos (data
not shown), and defects in turning or cardiac left–right
patterning were not observed in Smad1 mutants, unlike
those seen in Smad5 null embryos (Chang et al., 2000). This
is particularly surprising since surgical removal of the
allantois has previously been shown to cause defects in tail
sidedness in the developing rat embryo (Fujinaga and Baden,
1993; Fujinaga et al., 1995). These findings suggest distinct
roles for these two genes during murine development.
The defect in Smad1 mutants does not exactly pheno-
copy other ligand, receptor, or Smad mutants. The pheno-
type partially resembles defects in Bmp4 null embryos,
which fail to development an allantois on certain genetic
tA
d
B), 1
164 Lechleider et al.backgrounds, and Bmp5;7 double null embryos (see below).
Type-II receptor mutants either singly as in BmprII mu-
FIG. 5. VCAM-1 and Flk1 staining. (A, B) Low- (A) and high
Arrowheads indicate a vessel and the arrow shows a hematopoietic
(C) or mutant (D) 8.5-dpc embryos. Note VCAM-1 expression in
Staining in the allantois (a) is lost in the mutant, but is still pres
already fused with the chorion. (E) Whole-mount in situ hybridiza
allantois. Dorsal is up and right. Scale bar, 100 mm (A), 25 mm (ants (Beppu et al., 2000) or in combination, as with wctrIIA;ActrIIB double mutants (Song et al., 1999), lead to
efects in gastrulation, and not to specific allantois defects,
wer views of Smad12/2 9.5-dpc mutant allantois stained for Flk1.
. (C, D) VCAM-1 whole-mount immunostaining of heterozygous
eart (h), allantois (a), and yolk sac (y) of the normal littermate.
n the heart and yolk sac. The allantois of the normal embryo had
of Vcam1 in Smad12/2 embryo at 8.5 dpc. The arrow indicates the
mm (C–E).(B)-po
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the h
ent i
tionhile type-I receptor mutations either lead to pre- or
a
i
c
a
n
s
e
p
d
t
t
w
t
h
1
a
S
l
d
A
a
a
W
m
b
t
d
a
o
h
e
B
m
O
g
s
c
165Smad1 Knockout Mouseperigastrulation lethality or specific cardiovascular defects.
Other Smad mutations are either lethal at about the time of
gastrulation, as is the case for Smad2 and Smad4 (Goumans
nd Mummery, 2000), or lead to viable animals with defects
n immune (Yang et al., 1999; Datto et al., 1999) (Smad3) or
ardiac (Galvin et al., 2000) (Smad6) function. Thus it
ppears that Smad1, like the other Smad genes, plays a
on-redundant role in regulating murine development.
The murine allantois is an extraembryonic mesodermal
tructure that originates from precursors in the proximal
piblast that are allocated to the allantois from the posterior
rimitive streak region at the late streak stage, about 7.0
pc. The allantois fuses with another extraembryonic struc-
ure, the chorion, at about 8.5 dpc to form the chorioallan-
oic placenta which ultimately provides for nutrient and
aste exchange in the developing animal. Specific loss of
he allantois, or failure of allantois fusion with the chorion,
as been reported for few other mouse mutants (Downs,
998). Loss of the cell adhesion molecule VCAM-1 (Kwee et
l., 1995; Gurtner et al., 1995) or its receptor, a4-integrin
(Yang et al., 1995), leads to defects similar to those seen in
Smad1 mice. Although we observed a loss of VCAM-1
protein expression in the allantois of Smad1 mutants,
expression of VCAM-1 mRNA appeared unchanged.
Whether this difference is due to the lack of sensitivity of
the immunoassay, or represents a true difference is not
discernible from our data. Another possibility is that ex-
pression of VCAM-1 is delayed due to a defect in prolifera-
tion of the allantois, or a defect in distal differentiation.
This is not supported by the RNA expression nor by the fact
that flk1 is expressed in the mutant allantois. Vasculariza-
tion, and hence flk-1 expression, begins distally and extends
proximally (Downs et al., 1998), suggesting that distal
differentiation is at least initiated in Smad1 mutants even if
it is not properly regulated. Expression of other factors is
FIG. 6. Smad1 is not essential for growth inhibition induced by BM
cultured as described. Cells were assayed for [3H]thymidine incor
represent measurements from triplicate wells 1/2 SEM. Each genot
experiment is shown.likely necessary for chorioallantoic fusion regulated bymad1, since loss of VCAM-1 does not exactly phenocopy
oss of Smad1 (Gurtner et al., 1995; Kwee et al., 1995).
The ligands and receptors that activate Smad1 during
evelopment of the allantois remain to be fully determined.
nalysis of mutants homozygous null at both the Bmp7
nd Bmp5 locus demonstrated a role for these ligands in
llantois development (Solloway and Robertson, 1999).
hile loss of either ligand alone has no effect on develop-
ent prior to organogenesis, embryos homozygous null for
oth ligands display defects in allantois development, somi-
ogenesis, branchial arch formation, and heart and neural
evelopment (Solloway and Robertson, 1999). The cellular
nd molecular mechanisms of the failure of allantois devel-
pment in these embryos may be unrelated to Smad1,
owever, as Bmp5;7 mutants showed defects in mTwist
xpression which we did not observe in Smad1 mutants.
mp4 mutants can demonstrate a loss of the allantois on a
ixed 129SV/Black Swiss background (Lawson et al., 1999).
ur analysis was primarily performed on the same back-
round, but analysis on a pure 129Sv/Ev background was
imilar. Interestingly, the reported Bmp4 null phenotype
ompletely failed to form an allantois, while the Smad12/2
mutants demonstrate defects that are more consistent with
a failure to properly proliferate and differentiate. Finally,
mutants of Fgfr2 display failure of chorioallantoic fusion in
approximately one-third of mutant embryos (Xu et al.,
1998). In these animals, the molecular mechanism of the
defect is not known, but VCAM-1 and a4-integrin expres-
sion appeared normal. Whether FGFR2 and Smad1 cooper-
ate in a signaling pathway is not known, although synergy
between receptor tyrosine kinase and Smad signaling path-
ways has been observed in other systems (de Caestecker et
al., 1998). Fully determining the ligand and receptor path-
ways that are responsible for activation of Smad1 during
allantois development and its role in other developmental
Fibroblasts from wild-type (Left) or mutant (Right) embryos were
ion following a 24-h treatment with the indicated ligand. Points
as tested in at least two separate experiments and a representativeP2.
porat
ype wprocesses awaits further studies.
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